Monoclonal_antibody_3D-effect_blue&green_edited.png

Technology

revolutionizing ADCs with precision and innovation

Breakthrough
Linker Technology

Baylink's novel linkers expand payload diversity, enabling use of hydrophobic drugs.

Unique design features are incorporated in the linker technology to reduce off-target effects and improve payload delivery to tumors.

Innovative
Payloads

Baylink is developing innovative payloads beyond TOP1i and MMAE payloads.

Protein degrader ADCs using molecular glues and PROTAC payloads offer new therapeutic approaches and are under development

at Baylink.

Addressing
Key Challenges

Baylink tackles critical issues: improving therapeutic index, expanding payload diversity, and overcoming resistance.

This drives the next wave

of precision ADCs.

Core Linker Technology Enables Multiple Types of ADCs

Our core linker technology enables a new generation of Antibody-Drug Conjugates (ADCs), expanding payload diversity, widening therapeutic index, and overcoming resistance. With a panel of hydrophilic linkers, we ensure precise and effective drug delivery while minimizing off-target effects.

Degrader Antibody Conjugates (DAC)

Degrader ADCs expand payload diversity and target previously undruggable mechanisms.

Novel ADCs with Classical Payloads

These ADCs target novel tumor antigens with proven cytotoxic payloads, offering new treatment options for broad tumor applications.

Dual Delivery of Chemo & I/O

This approach combines chemotherapy and immuno-oncology, leveraging novel T cell checkpoint inhibitors and precise DAR control for optimized treatment.

BAYLINK'S

innovative linker design offers advantages over early generation linkers

Baylink’s linker design surpasses early-generation linkers with superior compatibility with hydrophobic payloads and high drug loading, and reduced non-specific uptake into healthy cells.

Degrader Antibody Conjugate Platform

Baylink is transforming cancer therapy with advanced protein degraders. These molecules target previously undruggable proteins, expanding treatment options. By directly degrading target proteins, they bypass resistance mechanisms and have shown promising results in clinical trials. Delivering these molecules with antibody conjugates allows targeted tumor delivery and reduced systemic toxicity.

Revolutionary Antibody Drug Conjugate Platform

Baylink’s approach incorporates specific linker design features to help reduce non-specific uptake into healthy cells, while delivering hydrophobic drug molecules with high DAR ratio.

This unprecedented capacity to unleash potent cytotoxic effects opens a new frontier in cancer treatment, offering hope for patients with previously difficult-to-treat cancers and those who have developed resistance to existing therapies.

Integrating Immunotherapy with Dual Payload ADCs

Baylink's innovative approach to cancer therapy combines the precision of Antibody-drug conjugates (ADCs) with the power of immunotherapy. Our dual-payload ADCs deliver a potent one-two punch: first, the ADC precisely targets and delivers a cytotoxic payload directly to cancer cells, minimizing harm to healthy tissues. Simultaneously, an immunotherapy component within the ADC enhances the body's own immune system to actively destroy cancer cells with long-lasting memory.